Cited by 1,995Gut microbiota and healthInflammatory Bowel DiseaseMetabolomics and Mass Spectrometry Studies

Gut microbiome structure and metabolic activity in inflammatory bowel disease

Open access
Franzosa, Eric A., Sirota-Madi, Alexandra, Avila-Pacheco, Julian, Fornelos, Nadine, Haiser, Henry J., Reinker, Stefan, Vatanen, Tommi, Hall, A. Brantley +19 more·2018·Nature Microbiology

Abstract

The inflammatory bowel diseases (IBDs), which include Crohn's disease (CD) and ulcerative colitis (UC), are multifactorial chronic conditions of the gastrointestinal tract. While IBD has been associated with dramatic changes in the gut microbiota, changes in the gut metabolome-the molecular interface between host and microbiota-are less well understood. To address this gap, we performed untargeted metabolomic and shotgun metagenomic profiling of cross-sectional stool samples from discovery (n = 155) and validation (n = 65) cohorts of CD, UC and non-IBD control patients. Metabolomic and metagenomic profiles were broadly correlated with faecal calprotectin levels (a measure of gut inflammation). Across >8,000 measured metabolite features, we identified chemicals and chemical classes that were differentially abundant in IBD, including enrichments for sphingolipids and bile acids, and depletions for triacylglycerols and tetrapyrroles. While > 50% of differentially abundant metabolite features were uncharacterized, many could be assigned putative roles through metabolomic 'guilt by association' (covariation with known metabolites). Differentially abundant species and functions from the metagenomic profiles reflected adaptation to oxidative stress in the IBD gut, and were individually consistent with previous findings. Integrating these data, however, we identified 122 robust associations between differentially abundant species and well-characterized differentially abundant metabolites, indicating possible mechanistic relationships that are perturbed in IBD. Finally, we found that metabolome- and metagenome-based classifiers of IBD status were highly accurate and, like the vast majority of individual trends, generalized well to the independent validation cohort. Our findings thus provide an improved understanding of perturbations of the microbiome-metabolome interface in IBD, including identification of many potential diagnostic and therapeutic targets.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41564-018-0306-4

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Many functional metabolomics studies do not measure functional properties of the metabolites themselves but determine function using correlation and guilt by association with known bioactive metabolites, transcription, or protein expression.

    “Many functional metabolomics studies do not measure functional properties of the metabolites themselves, but rather determine function using correlation and “guilt by association” with other known bioactive metabolites, transcription, or protein expression”

    From Connecting metabolome and phenotype: recent advances in functional metabolomics tools for the identification of bioactive natural products (2024) · cites this paper as [16]

    Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured
  • Changes in bile acid composition and concentrations are associated with metabolic disorders and inflammatory bowel disease, which increase colorectal cancer risk.

    “Changes in bile acid composition and concentrations have been associated with metabolic disorders and IBD, which increases risk for CRC.161, 162”
  • Multiple lines of evidence point towards central roles of gut microbiome perturbations in the pathogenesis of IBD.

    “Multiple lines of evidence point towards central roles of gut microbiome perturbations in the pathogenesis of IBD.”
  • GI metagenomes of IBD patients are markedly different from non-IBD controls, showing increased tolerance for oxidative stress and correlation with inflammatory markers.

    “The GI metagenomes of IBD patients are also markedly different from non-IBD controls, showing an increased tolerance for oxidative stress and a correlation with inflammatory markers (Franzosa et al., 2019).”

    From Viral Infections, the Microbiome, and Probiotics (2021) · cites this paper as Franzosa et al., 2019

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [55]Franzosa E Functionally profiling metagenomes and metatranscriptomes at species-level resolution Nature Methods (In Proof) PMC6235447 30377376

Cited by

Sorted by citations

Authors
Franzosa, E. A., Sirota-Madi, A., Avila-Pacheco, J., Fornelos, N., Haiser, H. J., Reinker, S., Vatanen, T., Hall, A. B., Mallick, H., McIver, L. J., Sauk, J. S., Wilson, R. G., Stevens, B. W., Scott, J. M., Pierce, K., Deik, A. A., Bullock, K., Imhann, F., Porter, J. A., Zhernakova, A., Fu, J., Weersma, R. K., Wijmenga, C., Clish, C. B., Vlamakis, H., Huttenhower, C., & Xavier, R. J.
Affiliations
  • Broad Institute (US)
  • Harvard University (US)
  • University Medical Center Groningen (NL)
  • Novartis (Switzerland) (CH)
Corresponding author
  • Huttenhower, Curtis
  • Xavier, Ramnik J.
Venue
Nature Microbiology
Published
2018-12-10
Volume
4
Issue
2
Pages
293-305
ISSN
2058-5276 (ISSN-L)
OpenAlex
W2903406988
Cited by
1,995
References
57
Citations by year
2026: 251 · 2025: 310 · 2024: 349 · 2023: 275 · 2022: 331 · 2021: 270 · 2020: 156 · 2019: 53
FWCI
42.87
Type
journal article
Language
en
Open access
Locations
  • Nature Microbiology (publishedVersion)
  • PubMed (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (acceptedVersion, other-oa)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • ResearchSpace (University of Auckland) (submittedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
Funders
  • National Science Foundation (1053486, CAREER, 1453942)
  • Crohn's and Colitis Foundation of America
  • Crohn's and Colitis Foundation
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek (864.13.013, 016.Vidi.178.056, SPI 92-266, 016.136.308)
  • National Institutes of Health (DBI-1053486)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK092405, R24DK110499, U54DK102557, U01DK097430, P30DK043351, P30DK040561)
  • H2020 European Research Council (715772)
  • FP7 Ideas: European Research Council (322698)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
Keywords
inflammatory bowel disease, Crohn's disease, ulcerative colitis, gut microbiota, gut metabolome, fecal calprotectin, sphingolipids, bile acids, triglycerides, tetrapyrroles, oxidative stress, diagnostic biomarkers, therapeutic target
MeSH terms
Gastrointestinal Microbiome, Colitis, Ulcerative, Crohn Disease, Feces, Humans, Inflammation, Inflammatory Bowel Diseases, Biomarkers, Leukocyte L1 Antigen Complex, Biodiversity, Metagenome, Metabolome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review